UY26776A1 - Inhibidores de 3-hidroxi-3-metilglutaril-coenzima a reductasa y métodos. - Google Patents

Inhibidores de 3-hidroxi-3-metilglutaril-coenzima a reductasa y métodos.

Info

Publication number
UY26776A1
UY26776A1 UY26776A UY26776A UY26776A1 UY 26776 A1 UY26776 A1 UY 26776A1 UY 26776 A UY26776 A UY 26776A UY 26776 A UY26776 A UY 26776A UY 26776 A1 UY26776 A1 UY 26776A1
Authority
UY
Uruguay
Prior art keywords
inhibitors
glutaril
coenzyme
reductase
hydroxy
Prior art date
Application number
UY26776A
Other languages
English (en)
Inventor
Jeffrey A Robl
Bang Chi Chen
Chong Qing Sun
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of UY26776A1 publication Critical patent/UY26776A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)

Abstract

Se proporcionan compuestos de la siguiente estructura que son inhibidores de HMG CoA reductasa y por lo tanto son activos para inhibir la biosíntesis de colesterol, modular los lípidos en suero sanguíneo, por ejemplo, disminuir el colesterol LDL o incrementar el colesterol HDL, y tratar la hiperlidemia, dislipidemia, hipertrigliceridemia y aterosclerosis así como enfermedades de alzheimer y osteoporosis; y sus sales farmacéuticamente aceptables de los mismos.
UY26776A 2000-06-15 2001-06-15 Inhibidores de 3-hidroxi-3-metilglutaril-coenzima a reductasa y métodos. UY26776A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21159400P 2000-06-15 2000-06-15

Publications (1)

Publication Number Publication Date
UY26776A1 true UY26776A1 (es) 2002-01-31

Family

ID=22787566

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26776A UY26776A1 (es) 2000-06-15 2001-06-15 Inhibidores de 3-hidroxi-3-metilglutaril-coenzima a reductasa y métodos.

Country Status (20)

Country Link
US (1) US20020028826A1 (es)
EP (1) EP1294696A2 (es)
JP (1) JP2004503541A (es)
KR (1) KR20030010720A (es)
CN (1) CN1436174A (es)
AR (1) AR028732A1 (es)
AU (1) AU2001266860A1 (es)
BR (1) BR0111571A (es)
CA (1) CA2412979A1 (es)
CZ (1) CZ20023931A3 (es)
EC (1) ECSP024386A (es)
HU (1) HUP0302955A3 (es)
IL (1) IL152718A0 (es)
MX (1) MXPA02012415A (es)
NO (1) NO20026011L (es)
PE (1) PE20011364A1 (es)
PL (1) PL362477A1 (es)
UY (1) UY26776A1 (es)
WO (1) WO2001096311A2 (es)
ZA (1) ZA200210102B (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
EP1309329A2 (en) * 2000-08-15 2003-05-14 Pfizer Products Inc. Therapeutic combination of a cetp inhibitor and atorvastatin
US6875867B2 (en) * 2001-06-06 2005-04-05 Bristol-Myers Squibb Company Process for preparing chiral diol sulfones and dihydroxy acid HMG CoA reductase inhibitors
DE60219793T2 (de) 2001-07-11 2008-01-24 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Verfahren zur Behandlung von Cytokin-Vermittelten Erkrankungen
IL160845A0 (en) 2001-09-14 2004-08-31 Tularik Inc Linked biaryl compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
AU2003225102A1 (en) * 2002-04-23 2003-11-10 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
BR0312778A (pt) * 2002-07-18 2005-05-03 Sankyo Co Composição farmacêutica para prevenção ou tratamento de arteriosclerose ou doenças derivadas de arteriosclerose, e, usos de um antagonista de receptor de adp e de um inibidor de acat
US20050192245A1 (en) * 2002-07-18 2005-09-01 Sankyo Company, Limited Medicinal composition for treating arteriosclerosis
CA2494061C (en) * 2002-07-31 2011-06-14 Wayne R. Danter Protein tyrosine kinase inhibitors
GB0220885D0 (en) * 2002-09-09 2002-10-16 Novartis Ag Organic compounds
US7629347B2 (en) * 2002-10-09 2009-12-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
FR2848452B1 (fr) * 2002-12-12 2007-04-06 Aventis Pharma Sa Application des inhibiteurs de recapture intestinale des acides biliaires pour la prevention et le traitement de la maladie d'alzheimer
KR20110117731A (ko) 2003-05-30 2011-10-27 랜박시 래보러터리스 리미티드 치환된 피롤 유도체와 ｈｍｇ―ｃｏ 억제제로서의 이의 용도
US20070161700A1 (en) 2004-12-28 2007-07-12 Kowa Company, Ltd. Inhibitor for the formation of y-secretase complex
US20080312189A1 (en) * 2004-03-05 2008-12-18 Eisai Co., Ltd. Cadasil Treatment with Cholinesterase Inhibitors
MXPA06011969A (es) * 2004-04-14 2006-12-15 Warner Lambert Co Combinacion terapeutica para tratamiento de la enfermedad de alzheimer.
DE602005025755D1 (de) * 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
TW200719916A (en) * 2005-04-12 2007-06-01 Psivida Inc HMGCoA reductase inhibitor combinations and uses thereof
WO2007016306A2 (en) * 2005-08-01 2007-02-08 Psivida Inc. HMGCoA REDUCTASE INHIBITOR CODRUGS AND USES THEREOF
AU2006313430B2 (en) 2005-11-08 2012-09-06 Ranbaxy Laboratories Limited Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
US7498359B2 (en) * 2006-02-07 2009-03-03 Mochida Pharmaceutical., Ltd. Composition and method for preventing recurrence of stroke
NZ594178A (en) * 2006-02-27 2013-02-22 Targeted Molecular Diagnostics Llc An ex vivo method of predicting toxicity to tyrosine kinase inhibitors
WO2007111027A1 (ja) * 2006-03-29 2007-10-04 Kowa Co., Ltd. トリグリセリド低下剤及び高インスリン血症改善剤
WO2008059519A2 (en) * 2006-09-25 2008-05-22 Glenmark Pharmaceuticals Limited A process for the preparation of intermediates of rosuvastatin
JP5571387B2 (ja) 2007-01-11 2014-08-13 クリティカル・アウトカム・テクノロジーズ・インコーポレイテッド 癌の治療のための化合物および方法
US8404275B2 (en) * 2007-07-01 2013-03-26 Vitalis Llc Combination tablet with chewable outer layer
KR100900044B1 (ko) * 2007-07-05 2009-06-01 한국식품연구원 3-하이드록시-3-메틸글루타릴 보조효소 ａ 환원효소 저해용펩타이드 및 이를 함유하는 고콜레스테롤로 인한 심장질환 및 심혈관계 질환 치료제
TWI432195B (zh) 2007-10-03 2014-04-01 Kowa Co 神經細胞死亡抑制劑
WO2009079797A1 (en) * 2007-12-26 2009-07-02 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
CA2730890C (en) 2008-07-17 2018-05-15 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
KR101104335B1 (ko) * 2009-03-06 2012-01-16 가톨릭대학교 산학협력단 알카노일화된 히알루론산으로 형성된 나노입자 및 그 제조방법
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
MX2013000824A (es) * 2010-07-21 2013-10-28 Nucitec Sa De Cv Forma de dosificacion diaria unica para la prevencion y tratamiento del sindrome metabolico.
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US8865900B2 (en) 2011-01-18 2014-10-21 Dsm Sinochem Pharmaceuticals Netherlands B.V. Methyltetrazole sulfides and sulfones
CN103313983B (zh) 2011-01-18 2016-06-29 中化帝斯曼制药有限公司荷兰公司 在碱存在下制备他汀类化合物的方法
US9150562B2 (en) 2011-01-18 2015-10-06 Dsm Sinochem Pharmaceuticals Netherlands B.V. Process for the preparation of diol sulfones
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
CA2853804C (en) 2011-10-28 2021-06-01 Vitalis Llc Anti-flush compositions
HUE032936T2 (en) 2011-12-09 2017-11-28 Dsm Sinochem Pharm Nl Bv A method for producing thioprecursors of statins
WO2013083718A1 (en) 2011-12-09 2013-06-13 Dsm Sinochem Pharmaceuticals Netherlands B.V. Process for the preparation of a statin precursor
JP6041985B2 (ja) * 2012-06-08 2016-12-14 ミレ ファイン ケミカル カンパニー リミテッド 結晶型ｔ−ブチル２−［（４Ｒ，６Ｓ）−６−ホルミル−２，２−ジメチル−１，３−ジオキサン−４−イル］アセテート及びその製造方法
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN112159403B (zh) 2020-09-30 2022-04-15 复旦大学 一种用于合成他汀类药物的关键中间体的制备方法
CN114213350B (zh) * 2021-12-29 2024-03-19 江苏福瑞康泰药业有限公司 一种他汀类药物中间体的制备方法
CN114437052B (zh) * 2021-12-31 2024-03-29 江苏阿尔法集团福瑞药业(宿迁)有限公司 一种利用连续流微通道反应器合成他汀类药物中间体的方法
CN114601039A (zh) * 2022-03-16 2022-06-10 江苏省农业科学院 一种提高热应激下绵羊发情率和受胎率的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506219A (en) * 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors

Also Published As

Publication number Publication date
IL152718A0 (en) 2003-06-24
MXPA02012415A (es) 2003-06-06
WO2001096311A2 (en) 2001-12-20
AU2001266860A1 (en) 2001-12-24
PE20011364A1 (es) 2002-02-27
KR20030010720A (ko) 2003-02-05
EP1294696A2 (en) 2003-03-26
JP2004503541A (ja) 2004-02-05
PL362477A1 (en) 2004-11-02
WO2001096311A3 (en) 2002-07-11
AR028732A1 (es) 2003-05-21
CA2412979A1 (en) 2001-12-20
CZ20023931A3 (cs) 2003-03-12
ZA200210102B (en) 2004-03-12
HUP0302955A3 (en) 2005-08-29
US20020028826A1 (en) 2002-03-07
BR0111571A (pt) 2003-07-01
NO20026011L (no) 2003-02-12
HUP0302955A2 (hu) 2003-12-29
NO20026011D0 (no) 2002-12-13
ECSP024386A (es) 2003-03-10
CN1436174A (zh) 2003-08-13

Similar Documents

Publication Publication Date Title
UY26776A1 (es) Inhibidores de 3-hidroxi-3-metilglutaril-coenzima a reductasa y métodos.
CR9465A (es) Compuestos mejorados farmacocineticamente
GT199900147A (es) 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
AR030700A1 (es) Compuestos inhibidores de la reductasa hmg-coa y las composiciones y combinaciones farmaceuticas que las contienen
BR0315296A (pt) Derivados do ciclohexanol espirocìclicos
CR7882A (es) Compuestos 2-(1H-Indazol-6-ilamino-benzamidas como inhibidores proteinquinasas utiles para el tratamiento de enfermedades oftalmicas
ES2115237T3 (es) Fenil heterociclos como inhibidores de la ciclooxigenasa-2.
GT200300053A (es) Compuestos que modulan la actividad de ppar
GT200300054A (es) Compuestos que modulan la actividad de ppar
UY26883A1 (es) Combinación terapéutica
PA8600301A1 (es) Compuestos que modulan la actividad de ppar y procedimientos de preparacion
BR0105457A (pt) Combinações terapêuticas para estimulação do crescimento ósseo
BRPI0410479A (pt) derivados de tetraidroisoquinolina como ativadores do ppar-(alfa)
PA8559401A1 (es) Sales de acido succinico de 5,7,14-triazatetraciclo (10.3.1.0 2,11.0 4, 9)-hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas.
PA8467401A1 (es) Procedimiento para tratar la insuficiencia cardiaca
BRPI0518300A2 (pt) derivados de Ácido 7-(2h-pirazol-3-il)-3,5-diidràxi-heptanàico como inibidores da hmg co-a reductase para o tratamento de lipidemia
BRPI0408477A (pt) compostos de éster de fosfato/sulfato e composições farmacêuticas para inibir a nima de interação com proteìna (pin 1) e uso dos mesmos
ES2180703T3 (es) Composiciones de vacunas para mamiferos que comprenden escualeno o escualano, un fosfolipido y un tensioactivo como adyuvante.
BR0013935A (pt) IsÈmeros oticamente ativos de cetotifeno e metabólitos terapeuticamente ativos dos mesmos
BRPI0409551A (pt) derivados de fosfato e método para a fosforilação de um composto que tem um grupo hidróxi secundário
PT1274685E (pt) Derivado de piridina-n-oxido e processo para a sua transformacao em compostos farmaceuticamente eficazes
HN2000000045A (es) Nuevas combinaciones farmaceuticas para inhibidores de la nos.
MA29482B1 (fr) Derives de benzothiazol-2-one derivatives en tant qu'inhibiteurs de lipase et de phospholipase
ECSP003707A (es) Diazepanes
PA8464601A1 (es) Combinaciones de estatina-eter carboxialquilico

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140204